Weight-Loss Drugs Cut Cardiovascular Risk

By Longevity Lab · Published: July 29, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

In the large SELECT trial, the weight-loss drug semaglutide, a GLP-1 receptor agonist, lowered the risk of cardiovascular events by about 20% in people with obesity and no diabetes. The trial enrolled more than 17,000 adults with overweight or obesity who already had cardiovascular disease, and followed them for several years. That finding changes how obesity is treated, and it speaks directly to healthy longevity: this is about preventing the most common causes of death in the world, not about losing weight for the sake of looks and a nicer number on the scale.

What GLP-1 agonists are

Glucagon-like peptide-1 (GLP-1) is a gut hormone released in response to food. It increases insulin production, reduces appetite and slows how quickly the stomach empties. Drugs such as semaglutide imitate that hormone. They were originally developed to treat Type 2 diabetes, but they turned out to produce marked weight loss, and that opened the door to their use against obesity.

What the SELECT trial found for semaglutide

SELECT enrolled more than 17,000 people with overweight or obesity and existing cardiovascular disease, but no diabetes. Here is what several years of follow-up showed.

• Semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, death from vascular causes) by about 20% compared with placebo. In trial language that composite endpoint is MACE — major adverse cardiovascular events.
• Participants also lost a noticeable amount of weight.
• This is the first large result of its kind for this drug class specifically in people without diabetes.

Why this matters for longevity: cardiovascular disease is the number one cause of death worldwide. A drug that measurably lowers that risk in a large group of people does more for healthy longevity than most fashionable anti-aging supplements with unproven effects.

What this does NOT mean

Do not get swept up in the hype. Semaglutide is not an elixir of youth. The benefit was shown in one specific group, people with obesity and high cardiovascular risk, and not in everyone. The drug has side effects, most often gastrointestinal ones such as nausea and changes in bowel habits, and loss of muscle mass and weight regain after stopping are both open questions. Losing muscle this way overlaps with Sarcopenia, the age-related decline in muscle mass and strength. It is also an expensive prescription medicine, not a way of living.

Semaglutide and healthy longevity: what it means

The main shift is treating obesity as a cardiometabolic problem rather than a number on the scale. Waist size, blood pressure, glucose, triglycerides and HDL are the markers that actually define Metabolic syndrome — the hidden pandemic of the 21st century, and they are what a doctor looks at first. But keep expectations honest.

• This is a prescription drug with side effects and a high cost.
• It does not replace food and movement. It adds to them, for specific medical reasons.
• Only a doctor decides whether to prescribe it.

Why this matters beyond weight loss

The real change SELECT brought is not measured in kilograms. It is a change of lens. For a long time obesity was treated for the sake of weight, and now there is a drug that directly lowers the risk of heart attack and stroke in people with obesity. That moves the conversation away from appearance and toward how many healthy years you get.

The GLP-1 agonist class is now being tested in other conditions tied to aging and metabolism: kidney disease, fatty liver disease and heart failure, with possible effects on the brain also under discussion. If even some of those lines hold up, this stops being a weight-loss drug and becomes a broad cardiometabolic tool.

Enthusiasm has limits, though. The drugs are expensive, they have to be taken long term, they cause gastrointestinal side effects, and weight often returns after they are stopped. Loss of muscle mass is a separate concern, which is why it makes sense to pair these medicines with enough protein and strength training instead of letting them stand in for lifestyle.

What this changes for the average person

For most people the main conclusion from SELECT is not that you should rush to ask for a prescription. It is a change of frame: obesity is not a cosmetic problem but a risk factor for the heart and blood vessels, and it is worth dealing with. For some people the tool will be a drug prescribed by a doctor, but the foundation stays the same for everyone: food, movement and sleep. If you want to see where you personally stand before that conversation, running your own blood pressure and cholesterol numbers through Heart Age QRISK turns them into the same kind of 10-year risk of heart attack or stroke that the trial measured.

One detail deserves its own mention: keeping your muscle. Rapid weight loss by any method can take muscle mass with it, and over the long run that works against health and longevity. So enough protein and strength training matter even during drug treatment, and it helps to follow lean mass rather than the scale alone, which is exactly what a Body composition assessment is for.

What stays the foundation regardless of medication:

• a balanced diet;
• regular physical activity, including strength training;
• enough sleep;
• keeping blood pressure, glucose and lipids in check.

Frequently asked questions

Source: Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM. 2023;389:2221–2232. PubMed →

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.